Literature DB >> 21293506

IBD in 2010: optimizing treatment and minimizing adverse events.

Bénédicte De Vroey1, Jean-Frédéric Colombel.   

Abstract

The management of IBD remains a challenge, with the main issue being to combine therapeutic efficiency with minimal side effects and optimal quality of life. Efforts towards achieving this objective continued in 2010—we discuss some of the most relevant publications and their potential impact on daily practice in the future.

Mesh：

Substances：

Year:  2011        PMID： 21293506     DOI： 10.1038/nrgastro.2010.218

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  9 in total

1.  Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease.

Authors:  Kuldeep Cheent; Jonathan Nolan; Sohail Shariq; Liina Kiho; Arabinda Pal; Jayantha Arnold
Journal:  J Crohns Colitis       Date:  2010-06-09       Impact factor: 9.071

2.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

3.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.

Authors:  Matthew J Grainge; Joe West; Timothy R Card
Journal:  Lancet       Date:  2010-02-08       Impact factor: 79.321

4.  Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.

Authors:  William J Sandborn; Jean Frederic Colombel; Matthew Frankel; Daan Hommes; James N Lowder; Lloyd Mayer; Scott Plevy; Pieter Stokkers; Simon Travis; Gert Van Assche; Daniel C Baumgart; Stephan R Targan
Journal:  Gut       Date:  2010-11       Impact factor: 23.059

5.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.

Authors:  Millie D Long; Hans H Herfarth; Clare A Pipkin; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-16       Impact factor: 11.382

6.  Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Authors:  Daniel C Baumgart; Stephan R Targan; Axel U Dignass; Lloyd Mayer; Gert van Assche; Daan W Hommes; Stephen B Hanauer; Uma Mahadevan; Walter Reinisch; Scott E Plevy; Bruce A Salzberg; Alan L Buchman; Grigor M Mechkov; Zahariy A Krastev; James N Lowder; Matthew B Frankel; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

7.  A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

Authors:  Scott Plevy; Bruce Salzberg; Gert Van Assche; Miguel Regueiro; Daniel Hommes; William Sandborn; Stephen Hanauer; Stephan Targan; Lloyd Mayer; Uma Mahadevan; Matthew Frankel; James Lowder
Journal:  Gastroenterology       Date:  2007-08-21       Impact factor: 22.682

Review 8.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.

Authors:  H Sokol; L Beaugerie
Journal:  Gut       Date:  2009-10       Impact factor: 23.059
  9 in total
  8 in total

Review 1.  Therapeutic implications of inflammasome in inflammatory bowel disease.

Authors:  Vishal Khatri; Ramaswamy Kalyanasundaram
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.834

2.  Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease.

Authors:  Muaria Gazouli; Ioanna Pachoula; Ioanna Panayotou; Georgios Chouliaras; Nicholas P Anagnou; George Chroussos; Eleftheria Roma
Journal:  Ann Gastroenterol       Date:  2012

3.  Experiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study.

Authors:  Annelie Lindberg; Bjöörn Fossum; Per Karlen; Lena Oxelmark
Journal:  BMC Complement Altern Med       Date:  2014-10-22       Impact factor: 3.659

4.  Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study.

Authors:  Lena Oxelmark; Annelie Lindberg; Robert Löfberg; Berit Sternby; Anders Eriksson; Sven Almer; Ragnar Befrits; Bjöörn Fossum; Per Karlén; Olle Broström; Curt Tysk
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-11       Impact factor: 2.566

5.  A Bioinformatic Approach for the Identification of Molecular Determinants of Resistance/Sensitivity to Cancer Thermotherapy.

Authors:  Mustafa Barbaros Düzgün; Konstantinos Theofilatos; Alexandros G Georgakilas; Athanasia Pavlopoulou
Journal:  Oxid Med Cell Longev       Date:  2019-11-11       Impact factor: 6.543

6.  Select a suitable treatment strategy for Crohn's disease: step-up or top-down.

Authors:  Qian-Qian Chen; Li Yan; Jun Wan
Journal:  EXCLI J       Date:  2014-02-13       Impact factor: 4.068

7.  Inflammatory bowel disease professionals' attitudes to and experiences of complementary and alternative medicine.

Authors:  Annelie Lindberg; Britt Ebbeskog; Per Karlen; Lena Oxelmark
Journal:  BMC Complement Altern Med       Date:  2013-12-10       Impact factor: 3.659

Review 8.  Trichuris suis ova therapy in inflammatory bowel disease: A meta-analysis.

Authors:  Xing Huang; Li-Rong Zeng; Feng-Song Chen; Jing-Ping Zhu; Meng-Hua Zhu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.